ulcerative colitis: An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
106 |
4. Check minimum number of eventsNone |
106 |
5. Include endpointsNone |
106 |
6. Filter based on genotype QC (FinnGen only) |
106 |
Control definitions (FinnGen only)
- Control exclude
- K11_ENERCOLNONINF
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- K51
- Name in latin
- Pseudopolyposis coli
Similar endpoints
↥List of similar endpoints to
Pseudopolyposis of colon
based on the number of shared cases.
Similar with more cases:
- Ulcerative colitis
- Inflammatory bowel disease
- Noninfective enteritis and colitis
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 578 | 213 | 362 |
| Only index persons | 556 | 208 | 348 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.37 | 48.91 | 49.79 |
| Only index persons | 49.04 | 48.02 | 49.65 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 106 | 50 | 56 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 48.57 | 42.83 | 53.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 94
- Matched controls
- 939
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K51.4
ICD-10 Finland
Inflammatory polyps
+∞
135.4
94
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
+∞
114.2
85
*
A07EC02
ATC
mesalazine; oral, rectal
1019.9
99.7
82
6
K51.5
ICD-10 Finland
Left sided colitis
+∞
89.3
71
*
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
+∞
79.9
65
*
L04AX01
ATC
azathioprine; systemic
247.2
57.4
54
5
A07EA02
ATC
hydrocortisone; rectal
+∞
54.6
47
*
K51.3
ICD-10 Finland
Ulcerative (chronic) rectosigmoiditis
+∞
50.7
44
*
UJF32
NOMESCO Finland
Coloscopy
30.7
44.0
78
128
K51.8
ICD-10 Finland
Other ulcerative colitis
+∞
36.9
33
*
UJF30
NOMESCO Finland
Ileoscopy through colon
31.6
35.7
49
31
A07EA06
ATC
budesonide; oral, local oral
249.8
34.2
33
*
K51.1
ICD-10 Finland
Ulcerative (chronic) ileocolitis
+∞
29.8
27
*
K51.0
ICD-10 Finland
Ulcerative (chronic) pancolitis
+∞
26.3
24
*
H02AB07
ATC
prednisone; oral
13.7
24.0
46
61
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
19.3
22.9
36
29
K50.9
ICD-10 Finland
Crohn disease, unspecified
+∞
19.4
18
*
H02AB06
ATC
prednisolone; systemic
7.9
18.5
72
275
K51.2
ICD-10 Finland
Ulcerative (chronic) proctitis
+∞
18.3
17
*
A07EC01
ATC
sulfasalazine; oral, rectal
13.3
17.5
32
35
K51
ICD-10 Finland
Ulcerative colitis
+∞
17.2
16
*
UJF14
NOMESCO Finland
Enteroscopy of ileoanal anastomosis
+∞
17.2
16
*
L01BB02
ATC
mercaptopurine; oral
+∞
13.9
13
*
A07EA01
ATC
prednisolone; rectal
+∞
13.9
13
*
UJF12
NOMESCO Finland
Enteroscopy through intestinal stoma
+∞
13.9
13
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.4
12.9
50
162
56310
ICD-8 Finland
Chronic enteritis and ulcerative colitis, Ulcerative colitis
+∞
12.8
12
*
K50.1
ICD-10 Finland
Crohn disease of large intestine
+∞
12.8
12
*
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
135.8
11.7
12
*
K50.0
ICD-10 Finland
Crohn disease of small intestine
+∞
11.7
11
*
D94
ICPC
Chronic enteritis/ulcerative colitis
+∞
11.7
11
*
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
20.2
9.7
14
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
9.6
57
259
K50.8
ICD-10 Finland
Other Crohn disease
+∞
9.5
9
*
P01AB01
ATC
metronidazole; oral, rectal
4.0
9.2
53
229
J01MA02
ATC
ciprofloxacin; systemic
3.9
9.1
53
232
O99.6
ICD-10 Finland
Diseases of the digestive system complicating pregnancy, childbirth and the puerperium
55.3
8.9
10
*
326
Kela drug reimbursment
Adalimumab, golimumab, infliximab and ustekinumab (intestinal diseases)
+∞
8.4
8
*
M07.5*K51.9
ICD-10 Finland
Arthropathy in ulcerative colitis
+∞
8.4
8
*
A07EC03
ATC
olsalazine; oral
+∞
8.4
8
*
WX002
NOMESCO Finland
Sedation and analgesia
4.4
8.0
32
99
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.8
7.8
39
146
JFH30
NOMESCO Finland
Total colectomy, mucosal proctectomy and ileoanal anastomosis without ileostomy
+∞
7.4
7
*
JFH33
NOMESCO Finland
Total colectomy, mucosal proctectomy, ileoanal anastomosis and ileostomy
+∞
7.4
7
*
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
10.6
7.0
13
14
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.8
6.8
19
39
JFG00
NOMESCO Finland
Closure of loop enterostomy without resection
74.6
6.5
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
6.2
29
101
J01MA12
ATC
levofloxacin; systemic
4.0
6.1
25
78
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
36
9.72
20.10
1.9
1.7
—
—
—
0
0
50
165
4.84
14.45
2.6
1.9
2.90
3.38
mg/l
0.67
40
143
84
492
4.41
9.65
15.2
9.4
4.35
4.15
e9/l
0.36
79
430
13
17
8.58
9.49
1.5
1.5
—
—
—
0
0
62
327
3.16
7.79
6.7
5.3
1.19
1.22
mmol/l
1.58
56
300
63
365
2.79
6.21
7.5
6.5
1.20
1.22
mmol/l
1.03
51
313
26
99
3.15
5.49
2.3
2.4
20.90
25.40
%
1.11
19
88
9
12
8.07
4.45
4.6
3.0
49.67
55.00
%
—
9
12
7
7
10.59
4.07
1.0
1.0
—
—
—
0
0
12
36
3.63
3.60
1.3
1.6
—
—
—
0
0
6
6
10.49
3.54
2.5
1.0
—
—
titre
—
0
0
48
298
2.12
3.46
1.8
1.9
92.59
95.52
pmol/l
0.17
29
151
7
10
7.40
3.42
1.0
1.1
—
—
—
0
0
12
40
3.26
3.08
4.8
2.2
97.03
184.37
ng/l
0.50
12
34
7
12
6.16
3.07
1.0
1.6
—
—
—
0
0
8
17
5.00
2.98
1.7
1.2
—
—
—
0
0
6
10
6.28
2.73
1.3
1.9
—
—
—
0
0
17
75
2.51
2.68
11.8
7.4
2.75
0.96
mmol/l
—
10
58
17
76
2.47
2.60
11.8
7.4
4.79
5.19
kpa
0.63
17
71
6
11
5.71
2.58
1.3
1.8
—
—
—
0
0
6
11
5.71
2.58
1.3
1.8
—
—
—
0
0
6
11
5.71
2.58
1.3
1.8
—
—
—
0
0
6
11
5.71
2.58
1.3
1.8
—
—
—
0
0
6
11
5.71
2.58
1.3
1.8
—
—
—
0
0
31
181
2.01
2.52
1.5
1.5
19.79
20.61
nmol/l
0.12
26
147
26
146
2.03
2.34
6.3
2.8
684.67
130.32
ng/l
0.53
15
99
6
14
4.47
2.18
1.3
1.4
—
—
—
0
0
29
174
1.92
2.16
1.5
1.7
0.75
0.83
mg/l
0.14
23
142
101
919
3.10
2.08
32.9
13.6
73.29
76.77
umol/l
0.94
101
919
6
15
4.17
2.07
1.5
1.5
—
—
—
0
0
6
16
3.91
1.96
1.3
1.4
—
—
—
0
0
6
16
3.91
1.96
1.5
1.5
—
—
—
0
0
32
209
1.76
1.80
2.0
2.0
—
—
—
0
0
52
390
1.65
1.76
5.1
3.8
—
—
—
0
0
5
14
3.69
1.63
1.4
1.4
—
—
—
0
0
18
104
1.88
1.48
4.1
6.0
0.98
0.99
mmol/l
0.03
18
95
6
23
2.70
1.39
1.2
1.3
—
—
—
0
0
29
198
1.64
1.37
1.4
1.4
0.76
1.21
u/ml
—
5
61
17
100
1.83
1.33
3.3
4.1
32.70
30.38
%
—
10
63
6
24
2.59
1.32
1.2
1.1
—
6.13
—
0
6
36
265
1.54
1.23
3.3
3.0
2.32
2.36
mmol/l
0.85
31
235
15
240
0.56
1.23
4.3
4.2
15.52
22.18
%
—
8
101
5
19
2.71
1.23
1.2
1.3
—
—
—
0
0
0
34
0.00
1.18
0.0
1.5
—
—
—
0
0
0
34
0.00
1.18
0.0
1.8
—
4.60
—
0
24
39
296
1.50
1.15
3.9
3.4
45.31
34.35
ng/l
0.21
25
197
5
21
2.45
1.10
1.8
1.1
—
—
—
0
0
11
61
1.90
1.03
4.1
3.4
55.00
63.67
ml/min/173m2
—
5
27
7
35
2.07
1.02
1.1
1.8
—
—
—
0
0
0
32
0.00
0.97
0.0
1.3
—
—
—
0
0
0
32
0.00
0.97
0.0
1.3
—
—
—
0
0
0
32
0.00
0.97
0.0
1.3
—
—
—
0
0
7
37
1.95
0.96
4.9
2.1
1.44
1.26
%
—
7
37
85
771
1.52
0.91
4.7
4.5
1.57
1.90
mu/l
2.07
74
710
72
636
1.41
0.86
4.0
4.0
15.05
14.70
pmol/l
0.48
64
584
8
48
1.72
0.81
1.1
3.4
4.84
4.56
pmol/l
—
8
40
6
33
1.87
0.80
1.2
2.0
—
—
—
0
0
29
225
1.40
0.74
6.0
3.3
0.00
0.00
estimate
—
9
86
5
26
1.97
0.71
3.0
1.3
—
—
—
0
0
5
27
1.89
0.69
1.2
1.8
—
—
—
0
0
5
28
1.82
0.67
1.4
1.0
—
—
—
0
0
5
28
1.82
0.67
1.4
1.0
—
—
—
0
0
80
734
1.37
0.65
32.5
14.2
13.87
13.59
%
0.92
80
725
87
811
1.41
0.62
24.3
12.3
38.75
41.26
%
1.14
62
619
13
91
1.49
0.56
3.5
2.3
11.62
14.94
nmol/l
0.70
13
85
7
46
1.56
0.49
9.9
9.4
0.94
1.36
%
—
7
46
7
46
1.56
0.49
9.9
9.3
0.59
0.72
%
—
7
46
7
50
1.43
0.46
1.0
1.3
160.43
308.64
mu/l
—
7
44
85
803
1.30
0.44
4.0
4.1
5.79
5.84
mmol/l
0.17
75
740
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
9
67
1.37
0.39
4.8
2.1
16.53
5.53
ug/l
—
9
59
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
8
108
0.72
0.30
1.4
1.7
—
—
—
0
0
5
37
1.37
0.24
3.0
1.3
—
—
—
0
0
36
328
1.15
0.22
5.7
3.2
—
—
—
0
0
82
790
1.17
0.22
5.5
5.1
39.11
39.19
mmol/mol
0.02
77
748
5
42
1.20
0.22
2.6
5.5
24.96
25.19
mmol/l
—
5
42
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
51
1.19
0.20
1.3
1.2
—
—
—
0
0
14
119
1.20
0.19
3.4
1.6
—
—
—
0
0
15
129
1.19
0.18
1.6
1.5
—
—
—
0
0
85
825
1.15
0.18
3.9
3.7
1.29
1.30
mmol/l
0.04
78
761
7
62
1.14
0.17
2.1
1.9
—
—
—
0
0
16
139
1.18
0.17
1.7
2.7
2.44
2.43
mmol/l
0.01
16
124
30
275
1.13
0.17
4.4
2.8
—
—
—
0
0
19
169
1.15
0.16
1.5
1.6
—
—
—
0
0
65
625
1.10
0.15
3.4
3.4
—
—
—
0
0
39
413
0.91
0.13
5.5
3.2
0.00
0.00
estimate
—
9
86
24
220
1.12
0.13
5.4
4.1
8.02
10.11
mg/mmol
0.11
17
142
10
85
1.19
0.13
4.7
3.0
—
—
—
0
0
39
412
0.92
0.12
6.7
4.5
0.00
0.00
estimate
—
10
87
88
864
1.11
0.10
4.5
4.2
4.60
4.68
mmol/l
0.26
83
804
5
48
1.04
0.09
2.4
1.9
—
—
—
0
0
8
75
1.07
0.07
4.8
1.5
—
—
—
0
0
8
77
1.04
0.07
4.9
1.5
—
—
—
0
0
13
120
1.09
0.05
2.1
1.9
—
—
—
0
0
88
872
1.05
0.02
4.8
4.6
2.74
2.82
mmol/l
0.29
81
806
81
803
1.04
0.01
25.2
11.0
89.61
86.03
ml/min/173m2
0.77
69
656
10
102
0.98
0.00
16.5
6.9
—
—
—
0
0
14
135
1.04
0.00
2.1
2.1
—
—
—
0
0
15
145
1.04
0.00
1.1
1.3
1.21
8.00
u/ml
—
7
62
42
416
1.02
0.00
5.3
3.3
0.00
0.00
estimate
—
10
80
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
4.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
86
860
1.00
0.00
4.4
4.1
1.42
1.42
mmol/l
0.03
80
797
Mortality – FinRegistry
↥Association
Association between endpoint COLONPSEUDOP and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| COLONPSEUDOP | 1.439 [1.04, 2.0] | 0.029 |
| Birth year | 0.987 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 56 out of 325 males with COLONPSEUDOP died.
Mortality risk
Mortality risk for people of age
years, who have COLONPSEUDOP.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.245% |
| 5 | No data | 1.514% |
| 10 | No data | 3.885% |
| 15 | No data | 7.248% |
| 20 | No data | 12.735% |
Relationships between endpoints
↥Index endpoint: COLONPSEUDOP – Pseudopolyposis of colon
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data